+ +

•  

   

     Western blot analysis of Phospho-lipase C beta 1 in rat Brain lysates using Phospho-lipase C beta 1 antibody.    

  
  

Carnitine palmitoyltransferase 2 (CPT2) is a mitochondrial enzyme critical for fatty acid β-oxidation, facilitating the transport of long-chain fatty acids into mitochondria for energy production. As a key component of the carnitine shuttle system, CPT2 catalyzes the conversion of acylcarnitines back to acyl-CoA esters, enabling their entry into the metabolic pathway. Deficiencies in CPT2 function are linked to metabolic disorders, including life-threatening hepatic encephalopathy, myopathy, and hypoketotic hypoglycemia, particularly in infants.

CPT2 antibodies are essential tools in biomedical research and diagnostics, widely used to detect and quantify CPT2 protein expression in tissues or cultured cells. They aid in studying mitochondrial dysfunction, lipid metabolism disorders, and tissue-specific CPT2 distribution. Commercial CPT2 antibodies are typically monoclonal or polyclonal, validated for applications like Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF). Researchers rely on these antibodies to investigate CPT2-related pathologies, evaluate therapeutic interventions, or assess gene expression in model organisms.

Quality validation of CPT2 antibodies is crucial, given potential cross-reactivity with homologous proteins (e.g., CPT1). Recent advances in antibody engineering have improved specificity, supporting precision in studies of metabolic diseases. Additionally, CPT2 antibodies contribute to neonatal screening programs and muscle biopsy analyses, bridging laboratory research with clinical diagnostics. Ongoing research focuses on optimizing antibody performance for emerging techniques like spatial proteomics and single-cell sequencing, further expanding their utility in metabolic disease research.